Celldex ends clinical trial By: MarketMinute.com Stock News March 07, 2016 at 14:20 PM EST Celldex Therapeutics Inc. (Nasdaq: CLDX) ended a Phase 3 clinical trial of its brain cancer vaccine Rintega. Shares of the biopharmaceutical plunged $4.42 to $3.77. Related Stocks: Celldex Therapeutics